| Title |
TRAF6 is required for BLyS-mediated NF-κB signaling in multiple myeloma cells
|
|---|---|
| Published in |
Medical Oncology, September 2015
|
| DOI | 10.1007/s12032-015-0671-2 |
| Pubmed ID | |
| Authors |
Xinfeng Wang, Jingjing Wang, Hong Liu, Ruirong Xu, Runsheng Ding, Shenhua Jiang, Xudong Wang, Hongming Huang |
| Abstract |
Tumor necrosis factor receptor-associated factor 6 (TRAF6) transduces signals from members of the IL-1R/TLR and TNFR superfamilies to the transcription factors NF-κB and AP1. Elevated expression of the TNF family member B-lymphocyte stimulator (BLyS) in multiple myeloma (MM) has been described recently. However, the precise process by which BLyS signals in myeloma cell remains unknown. Here, we identified increased expression of TRAF6 in MM patient cells and the MM cell lines U266, RPMI8226, and KM3. Furthermore, rhBLyS induced TRAF6 up-regulation in these cells in a dose-dependent manner. Both the classical and alternative NF-κB pathways were activated by rhBLyS treatment. Depletion of TRAF6 by siRNA decreased levels of p-p65 and p-p100, even after stimulation with rhBLyS. Down-regulation of TRAF6 also abrogated rhBLyS-mediated cell viability. These findings suggest that TRAF6 is required for BLyS-mediated NF-κB signaling in myeloma cells and is a potential molecular therapeutic target in MM. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 5 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 5 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 2 | 40% |
| Student > Bachelor | 1 | 20% |
| Researcher | 1 | 20% |
| Student > Master | 1 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 2 | 40% |
| Biochemistry, Genetics and Molecular Biology | 1 | 20% |
| Chemistry | 1 | 20% |
| Nursing and Health Professions | 1 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 September 2015.
All research outputs
#18,425,370
of 22,826,360 outputs
Outputs from Medical Oncology
#794
of 1,291 outputs
Outputs of similar age
#192,520
of 266,946 outputs
Outputs of similar age from Medical Oncology
#9
of 15 outputs
Altmetric has tracked 22,826,360 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,291 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,946 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.